KENALOG IN ORABASE Drug Patent Profile

« Back to Dashboard

When do Kenalog In Orabase patents expire, and when can generic versions of Kenalog In Orabase launch?

Kenalog In Orabase is a drug marketed by Delcor Asset Corp and is included in one NDA.

The generic ingredient in KENALOG IN ORABASE is triamcinolone acetonide. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kenalog In Orabase

A generic version of KENALOG IN ORABASE was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for KENALOG IN ORABASE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for KENALOG IN ORABASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Delcor Asset Corp	KENALOG IN ORABASE	triamcinolone acetonide	PASTE;DENTAL	012097-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Investment Scenario and Fundamentals Analysis for Kenalog in Orabase

Last updated: February 20, 2026

What Is Kenalog in Orabase?

Kenalog in Orabase combines triamcinolone acetonide, a corticosteroid, with a protective barrier in orabase material. It is used topically to treat oral inflammatory conditions such as aphthous ulcers and stomatitis. Marketed primarily in dental and dermatological contexts, it holds a niche position due to its specific application and the corticosteroid's anti-inflammatory effects.

Pharmacological Profile and Regulatory Status

Attribute	Details
Active Ingredient	Triamcinolone acetonide
Formulation	Topical paste in orabase
Indications	Oral inflammatory conditions, ulcerative stomatitis
Regulatory approvals	Approved in multiple countries including the US (FDA) and Europe (EMA)
Patent situation	Generally no patent exclusivity post-approval; compounded formulations are common

Market Dynamics and Competitive Landscape

Market Size and Growth

• The global oral care market was valued at approximately USD 32 billion in 2021, with anti-inflammatory and corticosteroid topical agents representing a niche segment estimated at USD 400 million, expected to grow at 3-5% annually [1].

• The prescription sales for Kenalog in Orabase are concentrated in North America, Europe, and select Asian markets, with notable demand from dental clinics and oral health specialists.

Competition

Competitors	Product Name	Formulation	Market Share (Estimated)
Topical corticosteroid gels	Orabase-S	Similar corticosteroid formulations	45%
Other corticosteroid oral pastes	Hydrocortisone paste	Hydrocortisone-based formulations	30%
Compounded topical corticosteroids	Custom compounding	Variable	25%

Patent and Regulatory Considerations

• Standard formulations are often off-patent after 10-15 years from initial approval.

• Companies lack exclusivity rights for the marketed drug, favoring generic competition.

• Regulatory pathways focus on ensuring safety and efficacy, with some markets requiring post-market surveillance data.

Key Investment Indicators

Revenue and Pricing

• Prescribed prices range from USD 10 to USD 25 per tube, with prescription volumes of approximately 2 million units annually in North America alone.

• Total sales revenue estimated at USD 20-25 million annually globally.

Cost Structure

• Manufacturing expenses approximate 20% of sales, including active ingredient production, formulation, packaging, and distribution.

• Marketing costs are relatively low due to its niche application, typically below 10% of sales.

Profitability and Margins

Metric	Estimated Value
Gross Margin	70-75%
Operating Margin	30-35%
Net Margin	20-25%

Risks and Challenges

• Increasing competition from generics post-patent expiry.

• Regulatory hurdles in emerging markets.

• Growing preference for alternative treatments and local compounded formulations.

• Potential price erosion driven by generic manufacturers.

Investment Outlook

• The product's niche status ensures some protected revenue, but this is diminishing with widespread availability of generics.

• Growth depends on expanding indications, geographic expansion, and physician awareness.

• There is limited scope for significant R&D investment due to the mature market status.

• Opportunities exist in partnering with dental health service providers or developing combination formulations.

Key Takeaways

• Kenalog in Orabase is a low-growth, niche corticosteroid product with stable revenue but faces increasing generic competition.

• Market expansion relies on geographic penetration and evolving oral health indications.

• Low manufacturing and marketing costs support profitability, but long-term prospects are limited by patent and regulatory challenges.

• The product is suitable for conservative, risk-averse investors seeking steady cash flow within mature pharmaceutical niches.

FAQs

1. Is Kenalog in Orabase patent-protected?

   • No. The core formulation is off-patent, leading to generic competition.

2. What are the main markets for Kenalog in Orabase?

   • North America, Europe, and select Asian countries.

3. Can new indications boost its market?

   • Potentially, but regulatory approval and clinical validation are required.

4. What is the typical price per unit?

   • USD 10 to USD 25 per tube.

5. What are the primary risks for investors?

   • Patent expiration, price erosion from generics, and regulatory limitations.

---

References

[1] Statista. (2022). Global oral care market size and growth. https://www.statista.com.